Literature DB >> 29511352

Regulation of inside-out β1-integrin activation by CDCP1.

Sara G Pollan1, Fangjin Huang1, Jamie M Sperger2, Joshua M Lang2, Colm Morrissey3, Anne E Cress4, C Y Chu1, Neil A Bhowmick1, Sungyong You1, Michael R Freeman1, Danislav S Spassov5, Mark M Moasser5, William G Carter6, Shakti Ranjan Satapathy7, Kavita Shah7, Beatrice S Knudsen8.   

Abstract

Tumor metastasis depends on the dynamic regulation of cell adhesion through β1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. Here, we demonstrate reduced CDCP1 expression in high-grade, primary prostate cancers, circulating tumor cells and tumor metastases of patients with castrate-resistant prostate cancer. CDCP1 is expressed in epithelial and not mesenchymal cells, and its cell surface and mRNA expression declines upon stimulation with TGFβ1 and epithelial-to-mesenchymal transition. Silencing of CDCP1 in DU145 and PC3 cells resulted in 3.4-fold higher proliferation of non-adherent cells and 4.4-fold greater anchorage independent growth. CDCP1-silenced tumors grew in 100% of mice, compared to 30% growth of CDCP1-expressing tumors. After CDCP1 silencing, cell adhesion and migration diminished 2.1-fold, caused by loss of inside-out activation of β1-integrin. We determined that the loss of CDCP1 reduces CDK5 kinase activity due to the phosphorylation of its regulatory subunit, CDK5R1/p35, by c-SRC on Y234. This generates a binding site for the C2 domain of PKCδ, which in turn phosphorylates CDK5 on T77. The resulting dissociation of the CDK5R1/CDK5 complex abolishes the activity of CDK5. Mutations of CDK5-T77 and CDK5R1-Y234 phosphorylation sites re-establish the CDK5/CDKR1 complex and the inside-out activity of β1-integrin. Altogether, we discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates β1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29511352      PMCID: PMC6824599          DOI: 10.1038/s41388-018-0142-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  77 in total

1.  Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling.

Authors:  Junichi Takagi; Benjamin M Petre; Thomas Walz; Timothy A Springer
Journal:  Cell       Date:  2002-09-06       Impact factor: 41.582

2.  The C2 domain of PKCdelta is a phosphotyrosine binding domain.

Authors:  Cyril H Benes; Ning Wu; Andrew E H Elia; Tejal Dharia; Lewis C Cantley; Stephen P Soltoff
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

Review 3.  Integrins: emerging paradigms of signal transduction.

Authors:  M A Schwartz; M D Schaller; M H Ginsberg
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

4.  Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.

Authors:  Jamie M Sperger; Lindsay N Strotman; Allison Welsh; Benjamin P Casavant; Zachery Chalmers; Sacha Horn; Erika Heninger; Stephanie M Thiede; Jacob Tokar; Benjamin K Gibbs; David J Guckenberger; Lakeesha Carmichael; Scott M Dehm; Philip J Stephens; David J Beebe; Scott M Berry; Joshua M Lang
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

5.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

Authors:  Aaron P Putzke; Aviva P Ventura; Alexander M Bailey; Canan Akture; John Opoku-Ansah; Müge Celiktaş; Michael S Hwang; Douglas S Darling; Ilsa M Coleman; Peter S Nelson; Holly M Nguyen; Eva Corey; Muneesh Tewari; Colm Morrissey; Robert L Vessella; Beatrice S Knudsen
Journal:  Am J Pathol       Date:  2011-05-04       Impact factor: 4.307

6.  Talin-driven inside-out activation mechanism of platelet αIIbβ3 integrin probed by multimicrosecond, all-atom molecular dynamics simulations.

Authors:  Davide Provasi; Ana Negri; Barry S Coller; Marta Filizola
Journal:  Proteins       Date:  2014-09-25

7.  CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma.

Authors:  Takamasa Uekita; Masamitsu Tanaka; Misato Takigahira; Yuri Miyazawa; Yukihiro Nakanishi; Yae Kanai; Kazuyoshi Yanagihara; Ryuichi Sakai
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

8.  Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death.

Authors:  Kuei-Hua Chang; Parminder Singh Multani; Kai-Hui Sun; Fabien Vincent; Yolanda de Pablo; Soumitra Ghosh; Ritika Gupta; Hyun-Pil Lee; Hyoung-Gon Lee; Mark A Smith; Kavita Shah
Journal:  Mol Biol Cell       Date:  2011-03-09       Impact factor: 4.138

9.  A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Authors:  Beatrice S Knudsen; Ping Zhao; James Resau; Sandra Cottingham; Ermanno Gherardi; Eric Xu; Bree Berghuis; Jennifer Daugherty; Tessa Grabinski; Jose Toro; Troy Giambernardi; R Scot Skinner; Milton Gross; Eric Hudson; Eric Kort; Ernst Lengyel; Aviva Ventura; Richard A West; Qian Xie; Rick Hay; George Vande Woude; Brian Cao
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

10.  Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia.

Authors:  Alessandra Bosutti; Jie Qi; Roberta Pennucci; David Bolton; Sabine Matou; Kamela Ali; Li-Huei Tsai; Jerzy Krupinski; Eugene B Petcu; Joan Montaner; Raid Al Baradie; Francesca Caccuri; Arnaldo Caruso; Giulio Alessandri; Shant Kumar; Cristina Rodriguez; Jose Martinez-Gonzalez; Mark Slevin
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more
  11 in total

1.  CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.

Authors:  Abdullah Alajati; Mariantonietta D'Ambrosio; Martina Troiani; Simone Mosole; Laura Pellegrini; Jingjing Chen; Ajinkya Revandkar; Marco Bolis; Jean-Philippe Theurillat; Ilaria Guccini; Marco Losa; Arianna Calcinotto; Gaston De Bernardis; Emiliano Pasquini; Rocco D'Antuono; Adam Sharp; Ines Figueiredo; Daniel Nava Rodrigues; Jonathan Welti; Veronica Gil; Wei Yuan; Tatjana Vlajnic; Lukas Bubendorf; Giovanna Chiorino; Letizia Gnetti; Verónica Torrano; Arkaitz Carracedo; Laura Camplese; Susumu Hirabayashi; Elena Canato; Gianfranco Pasut; Monica Montopoli; Jan Hendrik Rüschoff; Peter Wild; Holger Moch; Johann De Bono; Andrea Alimonti
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

2.  Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.

Authors:  Thomas Kryza; Tashbib Khan; Scott Lovell; Brittney S Harrington; Julia Yin; Sean Porazinski; Marina Pajic; Hannu Koistinen; Juha K Rantala; Tobias Dreyer; Viktor Magdolen; Ute Reuning; Yaowu He; Edward W Tate; John D Hooper
Journal:  Nat Chem Biol       Date:  2021-04-15       Impact factor: 15.040

3.  Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.

Authors:  Brittney S Harrington; Yaowu He; Tashbib Khan; Simon Puttick; Paul J Conroy; Thomas Kryza; Tahleesa Cuda; Kamil A Sokolowski; Brian Wc Tse; Katherine K Robbins; Buddhika J Arachchige; Samantha J Stehbens; Pamela M Pollock; Sarah Reed; S John Weroha; Paul Haluska; Carlos Salomon; Rohan Lourie; Lewis C Perrin; Ruby H P Law; James C Whisstock; John D Hooper
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

4.  A transcriptomic study of probenecid on injured spinal cords in mice.

Authors:  Yu-Xin Zhang; Sai-Nan Wang; Jing Chen; Jian-Guo Hu; He-Zuo Lü
Journal:  PeerJ       Date:  2020-01-03       Impact factor: 2.984

5.  CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Authors:  Yu Lun; Nozha Borjini; Noriko N Miura; Naohito Ohno; Nora G Singer; Feng Lin
Journal:  J Immunol       Date:  2021-06-07       Impact factor: 5.426

6.  HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.

Authors:  Jasmina Makarević; Jochen Rutz; Eva Juengel; Sebastian Maxeiner; Jens Mani; Stefan Vallo; Igor Tsaur; Frederik Roos; Felix K-H Chun; Roman A Blaheta
Journal:  Cells       Date:  2018-09-01       Impact factor: 6.600

7.  KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells.

Authors:  Madhura Patankar; Sinikka Eskelinen; Anne Tuomisto; Markus J Mäkinen; Tuomo J Karttunen
Journal:  Mol Med Rep       Date:  2019-09-20       Impact factor: 2.952

8.  CUB Domain-Containing Protein-1 Promotes Proliferation, Migration and Invasion in Cervical Cancer Cells.

Authors:  Lijun Huang; Yihong Chen; Shuyu Lai; Hongmei Guan; Xiaoling Hu; Jie Liu; Hanrong Zhang; Zhenfei Zhang; Jueyu Zhou
Journal:  Cancer Manag Res       Date:  2020-05-21       Impact factor: 3.989

9.  Effect of VX‑765 on the transcriptome profile of mice spinal cords with acute injury.

Authors:  Jing Chen; Yu-Qing Chen; Sai-Nan Wang; Fei-Xiang Duan; Yu-Jiao Shi; Shu-Qin Ding; Jian-Guo Hu; He-Zuo Lü
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

10.  Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.

Authors:  Thomas Kryza; Tashbib Khan; Simon Puttick; Chao Li; Kamil A Sokolowski; Brian Wc Tse; Tahleesa Cuda; Nicholas Lyons; Madeline Gough; Julia Yin; Ashleigh Parkin; Elena I Deryugina; James P Quigley; Ruby H P Law; James C Whisstock; Andrew D Riddell; Andrew P Barbour; David K Wyld; Paul A Thomas; Stephen Rose; Cameron E Snell; Marina Pajic; Yaowu He; John D Hooper
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.